Scrip: industry news and insights
Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.
The South Korean Securities & Futures Commission (SFC) has decided that Samsung BioLogics violated accounting standards by intentionally omitting information on its biosimilars joint venture agreement with US partner Biogen Inc. in public disclosures.
As a result, the SFC has decided to ask for the dismissal of Samsung BioLogics executives in charge of the matter and report the company and its CEO Tae Han Kim to prosecutors. It has also designated an external auditor for the company for three years.
The SFC has furthermore moved to restrict Samjong KPMG, Samsung BioLogics’ previous auditor, from auditing the company for four years and to report both the accounting company and its relevant employees to prosecutors for alleged violation of auditing standards.
However, the SFC delayed making a decision on the Financial Supervisory Service’s (FSS) claim that Samsung BioLogics had also illegally changed the corporate governance of the JV, which had initially been classed as a subsidiary, citing weak clarity and concreteness of the administrative measures. To resolve this issue, the SFC asked the service to conduct another inspection on the matter, and a final decision will be made after it reports the outcome to the SFC.
Samsung BioLogics and Biogen set up the biosimilars joint venture, Samsung Bioepis Co. Ltd., in 2012.
Meanwhile, Samsung BioLogics stated that it regretted the SFC's decision and reiterated that it had handled all of its accounting legally. The company will seek possible legal salvation steps, such as filing an administrative lawsuit, that would seek to recognize the appropriateness of its accounting and to protect investors and related parties.
Samsung BioLogics also stressed that the company would not be not subject to any possible delisting of its stock due to the latest SFC decision.
With the latest ruling, Samsung BioLogics has avoided - at least until the SFC makes a final decision on the key accounting issue - the worst case scenario of being the subject of a stock delisting review, but is still set to face potential negative impact on its credibility and business, and possibly in winning new contract manufacturing orders.
South Korean analysts expect uncertainties will remain until the authorities' final decision, but cautiously predicted it would avoid any delisting given its huge possible impact on the stock market and investors.
The ruling by the SFC, which is under the Financial Services Commission (FSC), comes after a series of meetings in the past few months. Financial authorities have spent the longest time on discussing the latest accounting issue case.
The SFC’s principal role is to investigate market abuses in the securities and futures markets and establish accounting standards and audit reviews. It conducts advance reviews of matters relating to the securities and futures markets to be deliberated by the FSC.
"All judgement has been made based on objective facts and international accounting standards. We have provided sufficient opportunities to the company and accounting firm by allowing them to state their opinions at the meetings, and aggressively listened to views by expert organizations such as the Korea Accounting Institute. In addition, we have come to the conclusion [on the irregularities] by respecting the expertise and judgement of three private members of the SFC," said the SFC in a statement.
According to the SFC, Samsung BioLogics had omitted disclosing some details of its joint venture agreement with Biogen, including on parts relating to a call option for the US firm to increase its stake, in the annotation of the South Korean company’s financial statements.
The SFC described this as a serious violation of accounting standards and the company had "recognized such possible violation," but "intentionally" omitted its disclosure.
In May, the FSS has sent a pre-notification to Samsung BioLogics after reportedly concluding that it had violated accounting standards when it changed in 2015 its accounting related to Samsung Bioepis. Samsung BioLogics had previously been reflecting Samsung Bioepis as a subsidiary in its consolidated financial statements, but then changed it to affiliated company status in that year.
As a result, Samsung BioLogics changed the value of its stake in Samsung Bioepis to market value from book value, which resulted in hefty one-off investment income. (Also see "Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV" - Scrip, 2 May, 2018.)
Samsung BioLogics insisted that it had made the change in accordance with IFRS (International Finance Reporting Standards) requirements, and that this had been confirmed as adequate by external auditors.
Earlier in July, Biogen Inc. exercised an option to purchase additional shares in Samsung Bioepis, which will raise its stake in the biosimilars venture to nearly 50%. (Also see "Biogen Ups Samsung Bioepis Stake In $700m Bet On Biosimilars " - Scrip, 2 Jul, 2018.)
From the editors of PharmAsia News.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topics Cell and gene therapy
Scrip: industry news and insights
By Joseph Haas
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: